No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

With Extensive Track Record in Advancing Adoption of Telehealth and Virtual Care, Kvedar to Help Accelerate Sweetch’s Global Growth

Editor: What To Know

  • Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.
  • Joseph Kvedar brings a deep understanding of remote health, digital therapeutics and reimbursement to Sweetch, and will focus on accelerating the commercial rollout and demonstrated positive clinical impact of the company's hyper-personalized platform, as well as building connections with strategic partners to further the company's success.
  • Mobile health devices could become a biological information superhighway that transfer data from our bodies or brains to the cloud for analysis and action, so long as the right content returns to the user to complete the cycle.

Prof. Joseph Kvedar has joined the Sweetch advisory board. Prof. Joseph Kvedar brings a deep understanding of remote health, digital therapeutics and reimbursement to Sweetch, and will focus on accelerating the commercial rollout and demonstrated positive clinical impact of the company’s hyper-personalized platform, as well as building connections with strategic partners to further the company’s success.

“During my almost 30 years of working in connected health innovation, few platforms or devices have excited me or shown as much promise in significantly impacting chronic disease management as Sweetch,” said Prof. Joe Kvedar. “The platform’s novel approach of combining and leveraging AI and EI (emotional intelligence) to have a meaningful impact on patient compliance could significantly change the way healthcare bodies interact with patients. I am proud to be playing a role at Sweetch during this crucial time of its growth.”

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age. He is also the current editor-in-chief of Nature’s open access, international, peer-reviewed journal, npj Digital Medicine.

In a 2015 Forbes article, a Prof. Kvedar quote served as inspiration for Sweetch’s work, stating: “The belief that new technology like body monitoring and data tracking is the key to a healthier and happier world ignores the huge role that engagement personalization plays in converting data and analytics into emotion that engages people in new health behaviors by humanizing our experience with technology. We need personalized, compelling and imaginative engagement that makes the user want to engage in self-care. People aren’t moved to action by “data dumps,” but by emotion and narrative. Mobile health devices could become a biological information superhighway that transfer data from our bodies or brains to the cloud for analysis and action, so long as the right content returns to the user to complete the cycle.”

“Prof. Kvedar is a valuable addition to Sweetch’s advisory board as we anticipate upcoming key milestones and the next stage of our company’s growth,” said Yoni Nevo, CEO of Sweetch. “Given his extensive experience in digital and remote health, Joe will be a major asset in achieving our objectives of improving how healthcare system players interact with their patients, empowering those with chronic conditions to comply with their treatment programs and attain their health goals.”

With decades of experience in digital health, Prof. Kvedar has been dedicated to driving innovation and using technology to empower patients, as well as their relationships with their care providers. Aspiring to evolve new models of healthcare delivery, Kvedar has developed innovative methods to move care from the hospital or doctor’s office into the day-to-day lives of patients. He has launched mobile health programs, virtual care initiatives and clinical research programs to improve care delivery and put patients at the center of their own health and wellness.

In July of this year, the company secured $20 Million Series A.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

VeraClinic: Pioneering Personal Transformation Through Hair Transplantation and Cosmetic Surgery in Turkey

As a testament to Turkey's legacy in the world of aesthetic medicine, VeraClinic invites you to discover the transformative power of our hair transplantation and cosmetic surgery services.

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy